The melanocortin-3 (MC3) and melanocortin-4 (MC4) receptors regulate energy homeostasis, food intake, and associated physiological conditions. The melanocortin-4 receptor (MC4R) has been studied extensively. Less is known about specific physiological roles of the melanocortin-3 receptor (MC3R). A major obstacle to this lack of knowledge is attributed to a limited number of identified MC3R selective ligands. We previously reported a spatial scanning approach of a 10-membered thioether-heterocycle ring incorporated into a chimeric peptide template that identified a lead nM MC4R ligand. Upon the basis of those results, 17 compounds were designed and synthesized that focused upon modification in the pharmacophore domain. Notable results include the identification of a 0.13 nM potent 5800-fold mMC3R selective antagonist/slight partial agonist versus a 760 nM mMC4R full agonist (ligand 11). Biophysical experiments (two-dimensional (1)H NMR and computer-assisted molecular modeling) of this ligand resulted in the identification of an inverse γ-turn secondary structure in the ligand pharmacophore domain.
The n class="Gene">melanocortin-3 (MC3) and melanocortin-4 (MC4) receptors regulate energy homeostasis, food intake, and associated physiological conditions. The melanocortin-4 receptor (MC4R) has been studied extensively. Less is known about specific physiological roles of the melanocortin-3 receptor (MC3R). A major obstacle to this lack of knowledge is attributed to a limited number of identified MC3R selective ligands. We previously reported a spatial scanning approach of a 10-membered thioether-heterocycle ring incorporated into a chimeric peptide template that identified a lead nM MC4R ligand. Upon the basis of those results, 17 compounds were designed and synthesized that focused upon modification in the pharmacophore domain. Notable results include the identification of a 0.13 nM potent 5800-fold mMC3R selective antagonist/slight partial agonist versus a 760 nM mMC4R full agonist (ligand 11). Biophysical experiments (two-dimensional (1)H NMR and computer-assisted molecular modeling) of this ligand resulted in the identification of an inverse γ-turn secondary structure in the ligand pharmacophore domain.
Authors: Jerry Ryan Holder; Rayna M Bauzo; Zhimin Xiang; Joseph Scott; Carrie Haskell-Luevano Journal: Bioorg Med Chem Lett Date: 2003-12-15 Impact factor: 2.823
Authors: Malcolm J Kavarana; Dev Trivedi; Minying Cai; Jinfa Ying; Matthew Hammer; Christopher Cabello; Paolo Grieco; Guoxia Han; Victor J Hruby Journal: J Med Chem Date: 2002-06-06 Impact factor: 7.446
Authors: M A Bednarek; T MacNeil; R Tang; R N Kalyani; L H Van der Ploeg; D H Weinberg Journal: Biochem Biophys Res Commun Date: 2001-08-24 Impact factor: 3.575
Authors: Anamika Singh; Andrzej Wilczynski; Jerry R Holder; Rachel M Witek; Marvin L Dirain; Zhimin Xiang; Arthur S Edison; Carrie Haskell-Luevano Journal: J Med Chem Date: 2011-02-09 Impact factor: 7.446
Authors: D Lu; D Willard; I R Patel; S Kadwell; L Overton; T Kost; M Luther; W Chen; R P Woychik; W O Wilkison Journal: Nature Date: 1994-10-27 Impact factor: 49.962
Authors: T K Sawyer; P J Sanfilippo; V J Hruby; M H Engel; C B Heward; J B Burnett; M E Hadley Journal: Proc Natl Acad Sci U S A Date: 1980-10 Impact factor: 11.205
Authors: Patrick Sweeney; Michelle N Bedenbaugh; Jose Maldonado; Pauline Pan; Katelyn Fowler; Savannah Y Williams; Luis E Gimenez; Masoud Ghamari-Langroudi; Griffin Downing; Yijun Gui; Colleen K Hadley; Stephen T Joy; Anna K Mapp; Richard B Simerly; Roger D Cone Journal: Sci Transl Med Date: 2021-04-21 Impact factor: 19.319
Authors: Anamika Singh; Marvin L Dirain; Andrzej Wilczynski; Chi Chen; Blake A Gosnell; Allen S Levine; Arthur S Edison; Carrie Haskell-Luevano Journal: ACS Chem Neurosci Date: 2014-08-26 Impact factor: 4.418